Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities

Clinical Oncology

Volumn 23, Issue 9, 2011, Pages 572-578

  Wright, F ^a   Spithoff, K ^b   Easson, A ^c   Murray, C ^d   Toye, J ^e   McCready, D ^c   Petrella, T ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e Orillia Soldiers' Memorial Hospital   (Canada)

Author keywords

Cutaneous melanoma; Excision margins; Practice guideline; Sentinel lymph node biopsy; Surgical treatment; Systematic review

Indexed keywords

DISULFINE BLUE; ISOSULFAN BLUE;

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LIMB MELANOMA; LIMB TUMOR; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MEDICAL LITERATURE; MELANOMA; MICROMETASTASIS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL TIME; SYSTEMATIC REVIEW; TRUNK MELANOMA;

EID: 80053384185     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.04.012     Document Type: Article

References (40)

1. Canadian cancer statistics 2010 2010, Canadian Cancer Society's Steering Committee, Canadian Cancer Society, Toronto.
2. Browman G.P., Levine M.N., Mohide E.A., et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995, 13:502-512.
3. Cutaneous melanoma: a national clinical guideline 2003, Scottish Intercollegiate Guidelines Network, Scottish Intercollegiate Guidelines Network, Edinburgh, Guideline no. 72. Available at: http://www.sign.ac.uk/pdf/sign72.pdf.
4. Improving outcomes for people with skin tumours including melanoma: the manual 2006, National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence, London, Available at: http://guidance.nice.org.uk/CSGSTIM.
5. Evidence-based clinical practice guideline: treatment of cutaneous melanoma 2007, American Society of Plastic Surgeons, American Society of Plastic Surgeons, Arlington Heights, Available at: http://www.plasticsurgery.org/Documents/Medical_Profesionals/Evidence-based-Clinical-Practice-Guideline-Treatment-of-Cutaneous-Melanoma.pdf.
6. Clinical practice guidelines for the management of melanoma in Australia and New Zealand 2008, Australian Cancer Network Melanoma Guidelines Revision Working Party, Wellington: Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Available at: http://www.nhmrc.gov.au/publications/synopses/_files/cp111.pdf.
7. Lens M.B., Nathan P., Bataille V. Excision margins for primary cutaneous melanoma. Updated pooled analysis of randomized controlled trials. Arch Surg 2007, 142:885-891.
8. Sladden M.J., Balch C., Barzilai D.A., et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009, (4). 10.1002/14651858.CD004835.
9. Leiter U., Buettner P.G., Bohnenberger K., et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol 2010, 17:129-137.
10. Lens M.B., Dawes M., Goodacre T., Bishop J.A.N. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg 2002, 137:1101-1105.
11. Haigh P.I., DiFronzo L.A., McCready D.R. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003, 46:419-426.
12. Veronesi U., Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991, 126:438-441.
13. Balch C.M., Soong S.J., Smith T., et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001, 8:101-108.
14. Cohn-Cedermark G., Rutqvist L.E., Andersson R., et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000, 89:1495-1501.
15. Khayat D., Rixe O., Martin G., et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003, 97:1941-1946.
16. Thomas J.M., Newton-Bishop J., A'Hern R., et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004, 350:757-766.
17. Sladden M., Barzilai S., Hollis S., et al. Surgical excision margins for localised cutaneous melanoma [intervention protocol]. Cochrane Database Syst Rev 2004, (3). 10.1002/14651858.CD004835.
18. Srigley J.R., McGowan T., MacLean A., et al. Standardized synoptic cancer pathology reporting: a population-based approach. J Surg Oncol 2009, 99:517-524.
19. Chambers A.J., Pasieka J.L., Temple W.J. Improvement in the accuracy of reporting key prognostic and anatomic findings during thyroidectomy by using a novel web-based synoptic operative reporting system. Surgery 2009, 146:1090-1098.
20. Karim R.Z., van den Berg K.S., Colman M.H., McCarthy S.W., Thompson J.F., Scolyer R.A. The advantage of using a synoptic pathology report format for cutaneous melanoma. Histopathology 2008, 52:130-138.
21. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
22. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Eng J Med 2006, 355:1307-1317.
23. Balch C.M., Gershenwald J.E., Soong S.J., et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010, 28:2452-2459.
24. Balch C.M., Gershenwald J.E., Soong S., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
25. Thomas J.M. Time for comprehensive reporting of MSLT-1. Lancet Oncol 2006, 7:9-10.
26. Grichnik J.M. Sentinel-node biopsy in melanoma. N Engl J Med 2007, 356:418-419.
27. Gershenwald J.E., Ross M.I. Is sentinel-node biopsy superior to nodal observation in melanoma?: commentary. Natl Clin Pract Oncol 2007, 4:278-279.
28. Gonzalez U. Cloud of sentinel node biopsy: unlikely survival benefit in melanoma. Arch Dermatol 2007, 143:775-776.
29. Calabro A., Singletary S.E., Balch C.M. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989, 124:1051-1055.
30. Henderson M.A., Burmeister B., Thompson J.F., et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial (ANZMTG 01.01/TROG 02.01). J Clin Oncol 2009, 27(18S). abstract LBA 9084.
31. Morton D.L., Wen D.R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392-399.
32. Jansen L., Nieweg O.E., Peterse J.L., Hoefnagel C.A., Valdés Olmos R.A., Kroon B.B.R. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000, 87:484-489.
33. Estourgie S.H., Nieweg O.E., Valdés Olmos R.A., Hoefnagel C.A., Kroon B.B.R. Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years. Ann Surg Oncol 2003, 10:681-688.
34. Morton D.L., Cochran A.J., Thompson J.F., et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial. Ann Surg 2005, 242:302-313.
35. Kretschmer L., Thoms K., Peeters S., Haenssle H., Bertsch H., Emmert S. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res 2008, 18:16-21.
36. Roulin D., Matter M., Bady P., et al. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution. Eur J Surg Oncol 2008, 34:673-679.
37. McMasters K.M., Noyes R.D., Reintgen D.S., et al. Lessons learned from the Sunbelt melanoma trial. J Surg Oncol 2004, 86:212-223.
38. Warycha M.A., Zakrzewski J., Ni Q., et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (≤1 mm). Cancer 2009, 115:869-879.
39. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19:2370-2380.
40. Eggermont A.M.M., Suciu S., Santinami M., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372:117-126.